HIGHLIGHTS OF UNION BUDGET 2026-27
1. At a Glance
- Union Budget 2026-27 presented by FM Nirmala Sitharaman on 1 February 2026 — her 8th consecutive budget and the first prepared at Kartavya Bhawan (replacing North Block) [S1][S2].
- Structured around 3 Kartavyas: (i) accelerating growth, (ii) building citizen capacity, (iii) Sabka Sath Sabka Vikas — anchored to the Viksit Bharat 2047 vision [S1][S5].
- Marks a continued fiscal consolidation glide path while sustaining record capex push for infrastructure and frontier manufacturing — high-yield for GS-III (Economy) prelims & mains [S3][S4].
2. Why in the News
- Tabled in Parliament on 1 Feb 2026; first budget housed in Kartavya Bhawan, the new Common Central Secretariat complex [S1].
- Announces flagship Biopharma SHAKTI (₹10,000 cr / 5 yrs), SME Growth Fund (₹10,000 cr), AVGC Content Creator Labs in 15,000 schools, and 5 Regional Medical Hubs [S1][S3][S5].
- Fiscal deficit target pegged at 4.3% of GDP (BE 2026-27), down from earlier years — signals continued post-FRBM consolidation [S2].
3. Background & Evolution
- Budget cycle governed by Article 112 (Annual Financial Statement) of the Constitution; presented since 2017 on 1 February (advanced from end-February) [general constitutional context].
- Halwa ceremony marks start of printing; budget presented in paperless form since 2021 via Union Budget Mobile App [contextual].
- 2026-27 budget continues themes from 2024-25 ("Viksit Bharat") and 2025-26 (Saptarishi/4 engines), now reframed as 3 Kartavyas [S1][S5].
- Fiscal deficit trajectory: 5.6% (RE 2024-25) → 4.8% (RE 2025-26) → 4.3% (BE 2026-27) [S2].
4. Core Static Facts
| Parameter | Value |
|---|---|
| Total Expenditure (BE 2026-27) | ₹53.5 lakh crore [S2] |
| Non-debt Receipts | ₹36.5 lakh crore [S2] |
| Fiscal Deficit | 4.3% of GDP [S2] |
| Debt-to-GDP | 55.6% (vs 56.1% RE 2025-26) [S2] |
| Public Capex | ₹12.2 lakh crore (from ₹11.2 lk cr BE 2025-26) [S2][S3] |
| Defence Capital Outlay | ₹2,19,306 crore (+17.6% over RE 2025-26) [S3] |
| MoHFW Allocation | ₹1,06,530.42 crore (~+10% over RE) [S3] |
| Biopharma SHAKTI | ₹10,000 cr / 5 yrs [S1][S3] |
| SME Growth Fund | ₹10,000 cr [S3] |
| - Implementing body: Ministry of Finance; Department of Economic Affairs (Budget Division) [S1]. | |
| - 6 growth-pillar interventions under First Kartavya: 7 strategic/frontier sectors manufacturing, legacy industries, Champion MSMEs, infrastructure, energy security, City Economic Regions [S1]. |
5. Multi-Dimensional Analysis
Economic - Capex multiplier sustained: ₹12.2 lk cr public capex (~3.6% of GDP) to crowd-in private investment [S2][S3]. - Debt-to-GDP slipping below 56% signals adherence to revised FRBM glide path announced in 2025-26 [S2]. - STT raised on F&O (futures 0.02→0.05%; options premium 0.1→0.15%) — curbs derivative speculation flagged by SEBI [S2].
Social - ₹10,000 cr Biopharma SHAKTI + 3 new NIPERs + upgrade of 7 NIPERs target affordable biologics access [S3]. - 5 Regional Medical Hubs positioned to scale medical tourism ("Heal in India") [S1]. - AVGC Content Creator Labs in 15,000 secondary schools + 500 colleges via IICT Mumbai — skilling at scale [S1].
Strategic / Industrial - "7 strategic and frontier sectors" prioritised for manufacturing scale-up — extends PLI logic to deep-tech [S1][S3]. - Defence capex +17.6% YoY signals continued indigenisation under Atmanirbhar Bharat [S3].
Administrative / Federalism - City Economic Regions introduces a new sub-national planning unit beyond states — federalism implications [S1]. - TCS rationalisation to 2% for alcoholic liquor/scrap/minerals & tendu leaves (5%→2%) — compliance ease for states' producers [S2].
Agriculture - Cooperative deduction extended to cotton seed & cattle feed suppliers; credit-linked subsidy for animal husbandry; Coconut Promotion Scheme [S3].
6. Recent Developments (last 12-18 months)
- 1 Feb 2026: Budget 2026-27 tabled; first at Kartavya Bhawan [S1].
- 31 Jan 2026: Economic Survey projected Real GDP growth 7.4% for FY 2025-26 [S4].
- Feb 2026: Department of Pharmaceuticals released Biopharma SHAKTI strategy paper [S3].
- 2025-26 Budget had introduced ₹12 lakh nil-tax threshold under new regime — carried forward [S6 contextual].
7. Prelims Hooks
- First Union Budget presented from Kartavya Bhawan — Budget 2026-27 [S1].
- 3 Kartavyas = Growth + Capacity + Sabka Sath Sabka Vikas [S1].
- Total expenditure BE 2026-27 = ₹53.5 lakh crore [S2].
- Fiscal deficit BE 2026-27 = 4.3% of GDP [S2].
- Public capex BE 2026-27 = ₹12.2 lakh crore [S2].
- Biopharma SHAKTI outlay = ₹10,000 cr over 5 yrs; involves 3 new + 7 upgraded NIPERs and 1000+ accredited clinical trial sites [S3].
- Defence capital outlay = ₹2.19 lakh crore (+17.6%) [S3].
- MoHFW allocation = ₹1,06,530.42 crore [S3].
- STT on futures raised from 0.02% → 0.05% [S2].
- TCS on tendu leaves cut from 5% → 2% [S2].
- AVGC labs: IICT Mumbai to assist setup in 15,000 schools + 500 colleges [S1].
- Debt-to-GDP BE 2026-27 = 55.6% [S2].
- Six intervention areas under First Kartavya; 7 strategic & frontier sectors identified for manufacturing scale-up [S1].
- 5 Regional Medical Hubs for medical tourism [S1].
- SME Growth Fund = ₹10,000 crore [S3].
8. Mains Relevance
- GS-III: Indian Economy — Government Budgeting; Mobilisation of Resources; Infrastructure; Industrial policy.
- GS-II: Government schemes (Biopharma SHAKTI, AVGC labs); Centre-State relations (City Economic Regions).
- Likely question stems: 1. "Critically examine the sustainability of India's capex-led growth strategy in light of Budget 2026-27." 2. "The introduction of 'City Economic Regions' marks a shift in India's urban-economic planning. Discuss." 3. "How does Budget 2026-27 align fiscal consolidation with the Viksit Bharat 2047 vision?"
9. Related Topics to Study Next
- FRBM Act, 2003 — fiscal deficit glide path context.
- Article 112 / 110 / 117 — constitutional budget framework.
- Economic Survey 2025-26 — GDP 7.4% projection [S4].
- PLI Scheme & 7 frontier sectors — manufacturing linkage.
- 15th/16th Finance Commission — federal devolution backdrop.
- NIPERs & Department of Pharmaceuticals — Biopharma SHAKTI delivery [S3].
- SEBI F&O regulation — context for STT hike [S2].
- AVGC-XR National Policy 2024 — basis of AVGC labs.
10. Common Errors / Trap Areas
- 3 Kartavyas ≠ Saptarishi (2023) ≠ 4 Engines (2025) — each budget has its own framing; do not conflate.
- Biopharma SHAKTI is under Department of Pharmaceuticals (Min. of Chemicals & Fertilizers), not DBT or MoHFW [S3].
- Fiscal deficit 4.3% is BE 2026-27; the RE 2025-26 figure (4.8%) is often confused.
- Kartavya Bhawan (new CCS building) ≠ North Block; first budget prepared there in 2026 [S1].
- Capex ₹12.2 lk cr is Centre's capex; gross Centre+State capex is higher — don't equate.
- STT changes apply to F&O; cash market STT unchanged [S2].
11. Sources
- [S1] HIGHLIGHTS OF UNION BUDGET 2026-27 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221455 — (tier 1)
- [S2] SUMMARY OF UNION BUDGET 2026-27 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221458 — (tier 1)
- [S3] Union Budget 2026-27 Analysis (PRS) — https://prsindia.org/files/budget/budget_parliament/2026/Union_Budget_Analysis-2026-27.pdf — (tier 1)
- [S4] India's Real GDP estimated to grow by 7.4% in FY 2025-26 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221389 — (tier 1)
- [S5] Union Budget 2026-27 focuses on 3 Kartavyas — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221452 — (tier 1)
- [S6] No income tax up to ₹12 lakh (Budget 2025-26 reference) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2098406 — (tier 1)